Interview with Ali Akyildiz, General Manager, IMS Health Turkey
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
IMS started to operate in Turkey through some other local companies in the late 60s. The first report was published in 1968. Since the inception of the local entity in 1990, it has grown significantly serving both local and multinational clients by providing information, technology solutions and professional services including consulting. Our information panel covers over 99% of the market in terms of pharmaceutical sales data and accepted as a gold standard in the industry. Our consulting team consists of 20 professional consultants and acting as a hub for Middle East to support our clients in solving their problems in portfolio strategy, market entry, mergers & acquisitions and commercial effectiveness.
Currently, IMS Turkey is serving more than 150 clients in these areas with about 140 professionals with our recent Cegedim acquisition.
Contact Details
Gazeteciler Mahallesi
Yazarlar Sokak – No. 8, 34394 Esentepe – Sisli
Istanbul
Turkey
Tel: +90 212 355 57 00
Before we start with the interview I noticed that previously you were in charge of other regions aside from turkey. Is that still the case? If not why did IMS…
Ufuk S. Kumrulu, general manager of Polifarma, and Vildan Kumrulu, member of the board, share how the company has strategized its internal investments in recent years and how it plans…
M. Sonay Gürgen, chairman of the board and general manager of Selçuk Ecza Deposu, Turkey’s largest pharma distributory, offers his insider take on the pharmaceutical value chain in Turkey, the…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Maria Fernanda Prado, managing director of Janssen Turkey, elaborates on the unique dynamics at play in Turkey; an important emerging market. Prado addresses the challenges, advantages, and opportunities that exist…
Philipp Haas, chairman and CEO of DEVA, discusses the company’s export strategy and current positioning in the international pharmaceutical playing field. Haas also covers the changing dynamics of the industry…
Turgut Tokgöz, secretary general of the Pharmaceutical Manufacturers Association of Turkey (IEIS), provides his take on the state of the Turkish pharmaceutical sector, highlighting the challenges that the industry faces…
Dr Orhan Mutlu Topal, general manager at Emre Ecza Ilac, offers an insider take on the Turkish vaccine industry, the challenges on the horizon for the Turkish pharmaceutical sector, and the…
Cem Kolak, founder and managing director of BL Turkey, the only Turkish Third Party Logistics (3PL) firm 100 percent dedicated to the biopharmaceutical and life sciences sectors, leverages his pioneering…
Meri Istiroti, group coordinator of Liv Hospital Group, shares the hospital’s success story since its beginning in 2013 to becoming a leading private healthcare institution dedicated to service, quality, and…
Emin Çakmak, chairman of the Turkish Healthcare Travel Council, offers deep insights into the healthcare travel industry and how it stretches beyond the commonly used term of “medical tourism”. Çakmak…
Elif Çelik, executive vice president of the Healthcare Division of Eczacıbaşı Group, explains the rationale behind the group’s divestment of its generics arm and its new strategy to establish itself…
Ece Kaşıkçı, General Manager, Bristol-Myers Squibb (BMS) Turkey, outlines how BMS’ groundbreaking immuno-oncology therapy has proudly become the first product of its kind to be registered and reimbursed in the…
See our Cookie Privacy Policy Here